Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1993-05-28
1995-01-24
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
514647, 514648, 564221, 564192, 564194, 564219, 5483041, 558262, 568329, A61K 31135, C07C23306
Patent
active
053843312
ABSTRACT:
5,6-Dehydronorketamine and derivatives retaining the .alpha.,.beta.-unsaturated carbonyl are disclosed. These end other Michael or Michael-type acceptors and adducts are shown to influence the replication, differentiation or maturation of blood cells, especially platelet progenitor cells. Accordingly, these compounds are used for treatment of thrombocytopenia.
REFERENCES:
patent: 2864844 (1958-12-01), Davisson
patent: 3254124 (1966-05-01), Stevens
patent: 5032396 (1991-07-01), Williams
patent: 5250732 (1993-10-01), Kogan et al.
Adams, et al., "Studies on the Biotransformation of Ketamine" Biomedical Mass Spectrometry 8(11)527-539 (1981).
Domino, et al., "Phencyclidine and Related Arylcyclohexdylamines: Present and Future Applications" Geneste, eds., NPP Books, Ann Arbor Mich., 1983 pp. 397-409.
Leung, et al., "Comparative Pharmacology in the Rat of Ketamine and its Two Principal Metabolites, Norketamine and (z)-6-Hydroxynorketamine" J. Med. Chem. 29:2396-2399 (1986).
Lohmann, et al., "Idiopathic Thrombocytopenia Treated With Paf-Acether Antagonist WEB 2086" Lancet p. 1147 (Nov. 1988).
Mason, et al., "Toxicology and Carcinogenesis of Various Chemicals Used in the Preparation of Vaccines" Clin. Toxicology 4(2):185-204 (Jun. 1971).
Ogura, et al., "Functional and Morphological Differentiation Induction of a Human Megakaryoblastic Leukemia Cell Line (MEG-01s) by Phorbol Diesters" Blood 72(1):49-60 (Jul. 1988).
Parcell, et al., "Synthesis of Ketamine Metabolites I and II and Some Anomalous Reactions of 6-Bromoketamine" J. Organic Chemistry 46(25):5055-5060 (Dec. 1981).
Sato, et al., "Establishment of a human leukaemic cell line (CMK) with megakaryocytic characteristics from a Down's syndrome patient with acute megakaryoblastic leukaemia" British J. of Heaematology 72:194-190 (1989).
Woolf et al., "Biotransformation of ketamine, (Z)-6-hydroxyketamine, and (e)-6-hydroxyketamine by rat, rabbit, and human liver microsomal preparations" Xenobiotica 17(7):839-847 (1987).
Kogan Timothy P.
Somers Todd C.
Cintins Marianne M.
Criares T. J.
Genentech Inc.
Winter Daryl B.
LandOfFree
Ketamine analogues for treatment of thrombocytopenia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Ketamine analogues for treatment of thrombocytopenia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ketamine analogues for treatment of thrombocytopenia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1468812